BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22907512)

  • 1. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy.
    Asmar R; Beebe-Dimmer JL; Korgavkar K; Keele GR; Cooney KA
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):62-6. PubMed ID: 22907512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression.
    Schiffmann J; Salomon G; Tilki D; Budäus L; Karakiewicz PI; Leyh-Bannurah SR; Pompe RS; Haese A; Heinzer H; Huland H; Graefen M; Tennstedt P
    Urol Oncol; 2017 May; 35(5):243-249. PubMed ID: 28161322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.
    Morlacco A; Dal Moro F; Rangel LJ; Carlson RE; Schulte PJ; Jeffrey KR
    Urol Oncol; 2018 Dec; 36(12):528.e1-528.e6. PubMed ID: 30446466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy.
    Shiota M; Yokomizo A; Takeuchi A; Imada K; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    J Surg Oncol; 2014 Sep; 110(4):476-81. PubMed ID: 24898352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abdominal obesity, hypertension, antihypertensive medication use and biochemical recurrence of prostate cancer after radical prostatectomy.
    Ohwaki K; Endo F; Hattori K
    Eur J Cancer; 2015 Mar; 51(5):604-9. PubMed ID: 25613441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer.
    Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A; Eto M
    Ann Surg Oncol; 2017 May; 24(5):1443-1450. PubMed ID: 27896516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.
    Bhindi B; Xie WY; Kulkarni GS; Hamilton RJ; Nesbitt M; Finelli A; Zlotta AR; Evans A; van der Kwast TH; Alibhai SM; Trachtenberg J; Fleshner NE
    Urology; 2016 Jul; 93():77-85. PubMed ID: 27015944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database.
    Jayachandran J; Aronson WJ; Terris MK; Presti JC; Amling CL; Kane CJ; Freedland SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):9-17. PubMed ID: 20056618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obesity, race, and long-term prostate cancer outcomes.
    Vidal AC; Oyekunle T; Howard LE; De Hoedt AM; Kane CJ; Terris MK; Cooperberg MR; Amling CL; Klaassen Z; Freedland SJ; Aronson WJ
    Cancer; 2020 Aug; 126(16):3733-3741. PubMed ID: 32497282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
    Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
    Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
    van Roermund JG; Kok DE; Wildhagen MF; Kiemeney LA; Struik F; Sloot S; van Oort IM; Hulsbergen-van de Kaa CA; van Leenders GJ; Bangma CH; Witjes JA
    BJU Int; 2009 Aug; 104(3):321-5. PubMed ID: 19220264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.
    Kimura M; Bañez LL; Gerber L; Qi J; Tsivian M; Freedland SJ; Satoh T; Polascik TJ; Baba S; Moul JW
    J Sex Med; 2012 Apr; 9(4):1174-81. PubMed ID: 22188861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy.
    Kim DS; Jeon SH; Chang SG; Lee SH
    Korean J Urol; 2015 Oct; 56(10):703-9. PubMed ID: 26495071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
    Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
    Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
    Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
    Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome is associated with more aggressive prostate cancer.
    Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
    Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Vidal AC; Howard LE; Sun SX; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):72-78. PubMed ID: 27698439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Lefebvre F; Blanchet-Deverly A; Michineau L; Blanchet P; Multigner L; Brureau L
    Prostate; 2022 Feb; 82(3):359-365. PubMed ID: 34905623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.